百时美施贵宝（Bristol Myers Squibb）发布了2025年关键的非通用会计准则（Non-GAAP）项目的指南假设。公司预计2025年总收入约为455亿美元，比市场共识的478.45亿美元低。收入受益于增长产品组合的持续强劲表现，但因Revlimid、Pomalyst、Sprycel和Abraxane等药物的仿制药冲击，核心产品组合预计收入将下降约18%至20%，此外约5亿美元的外汇影响也对收入有负面作用。调整后的每股收益范围预计为6.55美元至6.85美元。
以上内容来自Benzinga Earnings专栏，原文如下：
Financial Guidance Bristol Myers Squibb is providing key 2025 non-GAAP line-item guidance assumptions as outlined below. We estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which we expect to result in a revenue decline of approximately 18-20% of the Legacy Portfolio. This is expected to be partially offset by the continued strength of our Growth Portfolio. This guidance also reflects an approximate $500 million expected negative impact to revenue due to foreign exchange.
| 2025 Non-GAAP1 Line-Item Guidance | |
| Total Revenues (Reported & Ex-F/X) | ~$45.5 billion |
| Gross Margin % | ~72% |
| Operating Expenses2 | ~$16 billion |
| Other Income/(Expense) | ~$30 million |
| Tax Rate | ~18% |
| Diluted EPS | $6.55-$6.85 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.